Considerations for the Management and Triage of Ocular Oncology Cases during the COVID-19 Pandemic

Abstract

Dear Editor,SARS-CoV-2, the virus that causes COVID-19, is a novel pathogen. It is spreading rapidly in the USA, and our understanding of its behavior, transmissibility, and best practices to reduce risk for spread remain limited. Rationing of resources is already occurring in response to the COVID-19 pandemic. The purpose of this document is to lay a basic framework for ocular oncology care during the current pandemic. However, it is important to recognize the complexity of ocular oncology care and the need for flexibility within any guidelines. Exceptions will occur. Patients will need to be evaluated on a case-by-case basis.Treatment of ocular and adnexal malignancies is not considered elective. To the extent possible, ocular oncology surgical cases for malignant tumors and some vision-threatening benign tumors should proceed during the current COVID-19 pandemic. It is important to recognize that there is risk for transmission of SARS-CoV-2 during patient care, even by asymptomatic individuals. Therefore, risk to patients, physicians and staff, and the community at large, must be balanced with the necessity for urgent care. In some cases, the balance may shift to delayed care being more appropriate for safety and conservation of limited resources.Clinicians faced with making these decisions should consider the severity of a negative outcome (death, loss of an eye, loss of vision) together with the probability of such an outcome. In ocular oncology, particularly with regard to retinoblastoma screening, events may be quite rare but consequences of delayed care devastating. The balance during a pandemic should favor the value of maximizing benefits to the population [1]. The availability of local resources and perceived risk for COVID-19 exposure associated with care given a region’s burden of disease may also factor into decision-making. These decisions will not be simple, and in some cases, consultation with medical ethics may help with medical decision-making.In addition to the need to reduce the risk for virus transmission and preserve personal protective equipment (PPE), for ocular oncologists there may be competing obligations between patient survival, globe salvage, and vision. At this time, there is no recommendation to alter treatment algorithms to favor enucleation over globe salvage; however, patient survival must be prioritized. Informed consent to include COVID-19 risk is recommended. As the pandemic worsens, it is likely that prioritization of only the most urgent and emergent procedures may be necessary. There is precedent for such prioritization of surgical oncology cases by the American College of Surgeons [2]. In these situations, malignant tumors are prioritized over benign tumors, and the higher-grade malignancies expected to more immediately lead to death and/or permanent disability are prioritized over less aggressive malignancies. Lower risk and benign case may be amenable to deferred care via telemedicine. Multidisciplinary discussions for urgent and semiurgent cases may facilitate institutional case allocation by OR committees. In some cases, ophthalmic pathology resources may also be limited. Telepathology may be an option in these circumstances.In March 2020, the authors communicated with numerous experts within the USA as well as internationally, in both pandemic hotspots and in regions less impacted, to assist in creating this document. Separately, multiple formal surveys were initiated to gauge current COVID-associated practice patterns that reflect variations in practice focus and location. Preliminary results from one such study, assessing practice patterns among North American ocular oncologist members of the Collaborative Ocular Oncology Group, have recently been made available online [3]. Strong pre-existing research networks and subspecialty societies have aided ocular oncologists in the rapid conduct of research, an often overlooked but critically important component of the public health response. The results of these studies will assist in the development of any future guidelines for ocular oncology care during a similar public health emergency.Four levels of urgency in ocular oncology have been established: emergent, urgent, semiurgent, and nonurgent.Some surgical cases are believed to carry a higher risk for transmission of SARS-CoV-2 [4, 5]. In ocular oncology, these higher-risk procedures are primarily in the oculoplastics domain and are indicated with an asterisk below. Special precautions, including presurgical COVID-19 testing and use of full PPE, should be considered when performing these surgeries in which aerosolization of virus may be more likely to occur. For these procedures, if COVID testing is positive or unavailable and the case cannot be deferred, full PPE including powered air-purifying respirator is strongly recommended.The following procedures are considered emergent:The following procedures are considered urgent:The following procedures are considered semiurgent:The following procedures are considered nonurgent:Respectfully submitted,Alison H. Skalet, MD, PhDRichard C. Allen, MDCarol L. Shields, MDMatthew W. Wilson, MDPrithvi Mruthyunjaya, MDDan S. Gombos, MD FACSThis document has been endorsed by the American Association of Ophthalmic Oncologists and Pathologists (AAOOP) Board of Directors and the International Society of Ocular Oncology (ISOO) Board of Directors. These recommendations are available at the AAOOP website: http://www.aaoop.org/. Reprint with permission from the AAOOP.The authors wish to thank their colleagues from throughout the USA and around the world for their personal communications and contributions. They thank Dr. Robert Macauley for discussions pertinent to the medical ethics considerations.The authors have no proprietary or commercial interest in the materials discussed in this article. Dr. Alison Skalet is a consultant for Castle Biosciences Inc. and Immuncore Inc. Dr. Carol Shields is on the Science Advisory Board for Aura Biosciences Inc. and Immunocore Inc. Prithvi Mruthyunjaya is a consultant for Castle Biosciences Inc. The other authors have no disclosures.This work was supported by grant P30 EY010572 from the National Institutes of Health (Bethesda, MD, USA) and by unrestricted departmental funding from Research to Prevent Blindness (New York, NY, USA).A.H.S. and D.S.G. conceived the presented idea. A.H.S. and R.C.A. wrote the manuscript with input from all authors. A.H.S., R.C.A., C.L.S., M.W.W., P.M., and D.S.G. contributed substantively to the final paper.

Topics & Concepts